Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223944 · ClinicalTrials.gov registry record · Phase 3
A Gaucher Disease Gene Therapy Trial With FLT201
A Phase 3 study, sponsored by Spur Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 45
- Enrollment target
NCT07223944 is a Phase 3 study that is actively recruiting participants, run by Spur Therapeutics. The registered enrollment target is 45 participants.
The verdict
NCT07223944, a Phase 3 study, is actively recruiting participants, sponsored by Spur Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 45 participants
- Enrollment target
Study Summary
This study is a Phase 3, non-randomized, multicenter, efficacy and safety study in adult patients with Gaucher disease Type 1, on stable treatment with enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) for at least 2 years. The study aims to confirm the efficacy and safety of FLT201 in this population after discontinuation of ERT/SRT.
Interventions
- GENETIC FLT201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2026-04-07 |
| Est. Completion | 2032-10-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07223944
The ClinicalTrials.gov registry entry for NCT07223944 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spur Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FLT201 is the first listed.
NCT07223944 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07223944 about?
NCT07223944 is a clinical study titled "A Gaucher Disease Gene Therapy Trial With FLT201". This study is a Phase 3, non-randomized, multicenter, efficacy and safety study in adult patients with Gaucher disease Type 1, on stable treatment with enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) for at least 2 years. The study aims to confirm the efficacy and safety of FLT...
What is the current status of trial NCT07223944?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 45 participants. The study started on 2026-04-07. Estimated completion is 2032-10-01.
What interventions are being tested in trial NCT07223944?
The interventions under investigation include: FLT201 (GENETIC).
Who is sponsoring clinical trial NCT07223944?
This trial is sponsored by Spur Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.